Technical Analysis for ARAV - Aravive, Inc.

Grade Last Price % Change Price Change
F 5.2 0.39% 0.02
ARAV closed down 4.78 percent on Friday, April 16, 2021, on 47 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ARAV trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.39%
Oversold Stochastic Weakness 0.39%
Wide Bands Range Expansion -4.41%
Oversold Stochastic Weakness -4.41%
Wide Bands Range Expansion -4.94%
Oversold Stochastic Weakness -4.94%
Bullish Engulfing Bullish -3.70%
Narrow Range Bar Range Contraction -3.70%
Inside Day Range Contraction -3.70%
Wide Bands Range Expansion -3.70%
Older End-of-Day Signals for ARAV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 3 hours ago
60 Minute Opening Range Breakdown about 4 hours ago
Down 1% about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
Up 1% about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. It is developing AVB-S6-500, a GAS6 binding protein and AXL decoy receptor, for the treatment of ovarian cancer, as well as for renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is based in Houston, Texas.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Breast Cancer Treatment Of Breast Cancer Ovarian Cancer Acute Myeloid Leukemia Cell Biology Carcinoma Pancreatic Cancer Hematologic Malignancies Renal Cell Carcinoma Treatment Of Ovarian Cancer Bemcentinib Triple Negative Breast Cancer

Is ARAV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.94
52 Week Low 4.27
Average Volume 259,845
200-Day Moving Average 6.34
50-Day Moving Average 6.80
20-Day Moving Average 6.28
10-Day Moving Average 5.57
Average True Range 0.52
ADX 18.74
+DI 17.56
-DI 29.70
Chandelier Exit (Long, 3 ATRs ) 8.40
Chandelier Exit (Short, 3 ATRs ) 6.66
Upper Bollinger Band 8.25
Lower Bollinger Band 4.32
Percent B (%b) 0.22
BandWidth 62.46
MACD Line -0.47
MACD Signal Line -0.37
MACD Histogram -0.1046
Fundamentals Value
Market Cap 83.33 Million
Num Shares 16.1 Million
EPS -6.65
Price-to-Earnings (P/E) Ratio -0.78
Price-to-Sales 25.22
Price-to-Book 1.85
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.75
Resistance 3 (R3) 5.79 5.64 5.66
Resistance 2 (R2) 5.64 5.49 5.62 5.62
Resistance 1 (R1) 5.41 5.41 5.34 5.37 5.59
Pivot Point 5.26 5.26 5.22 5.24 5.26
Support 1 (S1) 5.03 5.11 4.96 4.99 4.77
Support 2 (S2) 4.88 5.03 4.86 4.74
Support 3 (S3) 4.65 4.88 4.71
Support 4 (S4) 4.61